Sanofi edges down on concerns over drugs pipeline, Acomplia delays
Shares in Sanofi-Aventis slipped back in morning deals amid
concerns over the pharmaceutical group's drugs pipeline and notably the
announced four-year delay to US approval of Acomplia, traders said. Sanofi shares were trading down 0.92 eur or 1.49 pct at
60.65, while the CAC-40 was up 9.75 points or 0.17 pct at 5,698.51.
Read the rest of this entry ... (216 words left)